Table 4.
Seropositivity rates and GMTs for anti-CS antibodies from Months 0 to 20 (ATP Cohort for Immunogenicity)
|
Group |
Timing |
N |
Seropositive |
GMT (EU/mL) |
|
|
|||
|---|---|---|---|---|---|---|---|---|---|
| n | % | 95% CI | value | 95% CI | |||||
| RTS,S/AS02D |
SCREENING |
141 |
33 |
23.4 |
16.7 |
31.3 |
0.3 |
0.3 |
0.4 |
| |
Post Dose 2 (Month 2) |
151 |
149 |
98.7 |
95.3 |
99.8 |
28.9 |
22.4 |
37.3 |
| |
Post Dose 3 (Month 3) |
143 |
141 |
98.6 |
95.0 |
99.8 |
69.5 |
53.9 |
89.6 |
| |
Post Dose 3 (Month 9) |
143 |
127 |
88.8 |
82.5 |
93.5 |
6.2 |
4.6 |
8.3 |
| |
Post Dose 3 (Month 14) |
142 |
107 |
75.4 |
67.4 |
82.2 |
3.0 |
2.2 |
4.0 |
| |
Post Dose 3 (Month 20) |
131 |
94 |
71.8 |
63.2 |
79.3 |
1.9 |
1.4 |
2.6 |
| Hepatitis B |
SCREENING |
152 |
39 |
25.7 |
18.9 |
33.4 |
0.4 |
0.3 |
0.4 |
| vaccine |
Post Dose 2 (Month 2) |
156 |
10 |
6.4 |
3.1 |
11.5 |
0.3 |
0.3 |
0.3 |
| |
Post Dose 3 (Month 3) |
144 |
2 |
1.4 |
0.2 |
4.9 |
0.3 |
0.2 |
0.3 |
| |
Post Dose 3 (Month 9) |
147 |
0 |
0.0 |
0.0 |
2.5 |
0.3 |
0.3 |
0.3 |
| |
Post Dose 3 (Month 14) |
139 |
2 |
1.4 |
0.2 |
5.1 |
0.3 |
0.2 |
0.3 |
| Post Dose 3 (Month 20) | 132 | 5 | 3.8 | 1.2 | 8.6 | 0.3 | 0.3 | 0.3 | |
Seropositive ≥ 0.5 EU/mL.
N = number of subjects with available results.
n/% = number/percentage of subjects with titre within the specified range.